# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Rachel Vatnsdal downgrades Pacific Biosciences (NASDAQ:PACB) from Overweight to Neutral.
Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target f...
Bernstein analyst Eve Burstein maintains Pacific Biosciences (NASDAQ:PACB) with a Outperform and lowers the price target fro...
Goldman Sachs analyst Matthew Sykes downgrades Pacific Biosciences (NASDAQ:PACB) from Buy to Neutral and lowers the price ta...
Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:PACB) with a Sector Outperform and lowers the price tar...
TD Cowen analyst Daniel Brennan maintains Pacific Biosciences (NASDAQ:PACB) with a Buy and lowers the price target from $12 ...
Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.